KR20040026679A - 택솔 인핸서의 합성 - Google Patents

택솔 인핸서의 합성 Download PDF

Info

Publication number
KR20040026679A
KR20040026679A KR10-2004-7000333A KR20047000333A KR20040026679A KR 20040026679 A KR20040026679 A KR 20040026679A KR 20047000333 A KR20047000333 A KR 20047000333A KR 20040026679 A KR20040026679 A KR 20040026679A
Authority
KR
South Korea
Prior art keywords
group
substituted
nhr
phenyl
compound
Prior art date
Application number
KR10-2004-7000333A
Other languages
English (en)
Korean (ko)
Inventor
소우준 첸
리준 선
치-퀴앙 지아
케이조 코야
미츠수노리 오노
Original Assignee
신타 파마슈티칼스 코프.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신타 파마슈티칼스 코프. filed Critical 신타 파마슈티칼스 코프.
Publication of KR20040026679A publication Critical patent/KR20040026679A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
KR10-2004-7000333A 2001-07-10 2002-07-10 택솔 인핸서의 합성 KR20040026679A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30431801P 2001-07-10 2001-07-10
US60/304,318 2001-07-10
PCT/US2002/021716 WO2003006429A1 (en) 2001-07-10 2002-07-10 Synthesis of taxol enhancers

Publications (1)

Publication Number Publication Date
KR20040026679A true KR20040026679A (ko) 2004-03-31

Family

ID=23176001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7000333A KR20040026679A (ko) 2001-07-10 2002-07-10 택솔 인핸서의 합성

Country Status (11)

Country Link
US (4) US6825235B2 (US07652168-20100126-C00075.png)
EP (1) EP1406868A1 (US07652168-20100126-C00075.png)
JP (1) JP2004534847A (US07652168-20100126-C00075.png)
KR (1) KR20040026679A (US07652168-20100126-C00075.png)
CN (2) CN100398516C (US07652168-20100126-C00075.png)
AU (2) AU2002316625B2 (US07652168-20100126-C00075.png)
CA (1) CA2453415A1 (US07652168-20100126-C00075.png)
MX (1) MXPA04000245A (US07652168-20100126-C00075.png)
NO (1) NO20040053L (US07652168-20100126-C00075.png)
TW (1) TWI252847B (US07652168-20100126-C00075.png)
WO (1) WO2003006429A1 (US07652168-20100126-C00075.png)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
DK1781604T3 (da) * 2004-06-23 2013-09-16 Synta Pharmaceuticals Corp Bis(thio-hydrazid-amid)-salte til behandling af cancere
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
EP1827410A2 (en) * 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Bis(thio-hydrazide amides) for increasing hsp70 expression
AU2006236534A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
WO2006113695A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
WO2006124736A2 (en) * 2005-05-16 2006-11-23 Synta Pharmaceuticals Corp. Synthesis of bis(thio-hydrazide amide) salts
EP1940375A1 (en) 2005-08-16 2008-07-09 Synta Pharmaceuticals Corporation Bis(thio-hydrazide amide) formulation
BRPI0716435A2 (pt) * 2006-08-21 2014-03-04 Synta Pharmaceuticals Corp Compostos para o tratamento de doenças proliferativas
AU2007288334A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
WO2008024301A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
JP2010501564A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫を治療するためのビス（チオヒドラジドアミド）
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ
CN101134057B (zh) * 2006-09-01 2011-04-27 中山大学 含紫杉醇的天然植物提取物的复方药物及其抗癌应用
AU2007294969A1 (en) * 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
TW200829543A (en) * 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8637704B2 (en) 2007-11-28 2014-01-28 Synta Pharmaceuticals Corp. Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
WO2009105257A1 (en) 2008-02-21 2009-08-27 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8633323B2 (en) * 2008-03-31 2014-01-21 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
CN102256949B (zh) 2008-10-22 2014-09-24 辛塔医药品有限公司 双[硫代酰肼酰胺]化合物的过渡金属络合物
BRPI0919720A2 (pt) 2008-10-22 2015-12-08 Synta Pharmaceuticals Corp complexos de metal de transição de compostos bis-[tio hidrazida amida
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
EP2370402A2 (en) 2008-12-01 2011-10-05 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8822532B2 (en) 2009-12-04 2014-09-02 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
US8815945B2 (en) 2010-04-20 2014-08-26 Masazumi Nagai Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
JP2014534238A (ja) 2011-11-10 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）化合物の投与
US20150057357A1 (en) 2012-01-05 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers
WO2013144228A1 (en) 2012-03-29 2013-10-03 Basf Se Pesticidal methods using heterocyclic compounds and derivatives for combating animal pests
CN115572249A (zh) * 2022-09-21 2023-01-06 南京红云生物科技有限公司上海分公司 一种铜离子螯合剂及其制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH482394A (de) * 1966-09-14 1969-12-15 Shell Int Research Herbizides Mittel
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) * 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (US07652168-20100126-C00075.png) 1973-12-17 1975-07-21
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US4826866A (en) * 1987-11-02 1989-05-02 A. H. Robins Company, Incorporated 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics
US5300278A (en) * 1988-03-09 1994-04-05 Cis Bio International Process for the preparation of 99m Tc, 186 Re or 188 Re nitride complexes usable as radiopharmaceutical products
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
CN1245156C (zh) * 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
EP0763014A1 (de) 1994-06-03 1997-03-19 Basf Aktiengesellschaft Carbamoylcarbonsäurehydrazide und ihre verwendung zur bekämpfung von schadpilzen
CA2166676C (en) * 1995-01-09 2007-05-01 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
DE69604298T2 (de) * 1995-09-22 2000-05-18 Bioimage A S Soeborg Varianten des grünen fluoreszenzproteins, gfp
US5739686A (en) * 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US5753200A (en) * 1996-10-07 1998-05-19 Solvay Minerals, Inc. Sodium metabisulfite process
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6322303B1 (en) * 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) * 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
JP2004532187A (ja) * 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
TWI231211B (en) * 2001-05-01 2005-04-21 Abbott Lab Compositions and methods for enhancing the bioavailability of pharmaceutical agents
US20040235813A1 (en) * 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
EP1405841B1 (en) * 2001-06-20 2006-08-16 Kuraray Co., Ltd. Process for preparation of 2-oxocarboxylic acid esters
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MY133406A (en) * 2001-11-28 2007-11-30 Ipsen Pharma Sas 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
KR100958618B1 (ko) * 2002-12-31 2010-05-20 동부일렉트로닉스 주식회사 반도체 장치의 제조 방법
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
KR101166749B1 (ko) 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR100544347B1 (ko) * 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
BRPI0509172A (pt) 2004-03-26 2007-08-28 Amphora Discovery Corp pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
DK1781604T3 (da) 2004-06-23 2013-09-16 Synta Pharmaceuticals Corp Bis(thio-hydrazid-amid)-salte til behandling af cancere
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
WO2006062732A2 (en) 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
EP1827410A2 (en) * 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Bis(thio-hydrazide amides) for increasing hsp70 expression
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
AU2006236534A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
WO2006113695A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
WO2006124736A2 (en) * 2005-05-16 2006-11-23 Synta Pharmaceuticals Corp. Synthesis of bis(thio-hydrazide amide) salts
EP1940375A1 (en) * 2005-08-16 2008-07-09 Synta Pharmaceuticals Corporation Bis(thio-hydrazide amide) formulation
SI22254A (sl) 2006-04-13 2007-10-31 Univerza V Ljubljani Fakulteta Za Farmacijo NOVI ARILSULFONOHIDRAZIDNI INHIBITORJI ENCIMOV MurC IN MurD
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
AU2007288334A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
JP2010501564A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫を治療するためのビス（チオヒドラジドアミド）
WO2008024301A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
BRPI0716435A2 (pt) 2006-08-21 2014-03-04 Synta Pharmaceuticals Corp Compostos para o tratamento de doenças proliferativas
WO2008024302A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
JP2010502616A (ja) * 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ
AU2007294969A1 (en) * 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
JP2010503674A (ja) 2006-09-14 2010-02-04 シンタ ファーマシューティカルズ コーポレーション 血管形成治療用化合物
TW200829543A (en) * 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8093425B2 (en) * 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
TW200922550A (en) 2007-08-07 2009-06-01 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8637704B2 (en) 2007-11-28 2014-01-28 Synta Pharmaceuticals Corp. Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
TW200940050A (en) * 2007-11-28 2009-10-01 Synta Pharmaceuticals Corp Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide)

Also Published As

Publication number Publication date
US7652168B2 (en) 2010-01-26
AU2002316625B2 (en) 2006-05-25
US20030069225A1 (en) 2003-04-10
MXPA04000245A (es) 2005-03-07
NO20040053L (no) 2004-02-10
TWI252847B (en) 2006-04-11
CA2453415A1 (en) 2003-01-23
WO2003006429A1 (en) 2003-01-23
AU2006203689A1 (en) 2006-09-14
CN1553893A (zh) 2004-12-08
US20090005594A1 (en) 2009-01-01
US20040229952A1 (en) 2004-11-18
US7435843B2 (en) 2008-10-14
US6825235B2 (en) 2004-11-30
EP1406868A1 (en) 2004-04-14
JP2004534847A (ja) 2004-11-18
US7074952B2 (en) 2006-07-11
CN100398516C (zh) 2008-07-02
CN101270069A (zh) 2008-09-24
US20060281811A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
KR20040026679A (ko) 택솔 인핸서의 합성
AU2002316625A1 (en) Synthesis of taxol enhancers
KR890002104B1 (ko) 4-치환된-2-아제티디논 화합물의 제조방법
PT2280696E (pt) Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios com ele relacionados
CN106459014B (zh) 雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物
Bodor et al. A convenient synthesis of (acyloxy) alkyl. alpha.-ethers of phenols
WO2000047561A1 (en) Non-nucleoside reverse transcriptase inhibitors
CN1072213C (zh) 胍衍生物的制备方法及其中间体
Boyer et al. Synthesis of α, α‐Difluoro‐β‐amino Esters or gem‐Difluoro‐β‐lactams as Potential Metallocarboxypeptidase Inhibitors
CN109265390A (zh) 一种用于合成抗肿瘤药物niraparib的中间体的制备方法及中间体
JPH0215533B2 (US07652168-20100126-C00075.png)
JP2543958B2 (ja) デスフェリオキサミンｂのアシル化方法
KR100278119B1 (ko) 에르도스테인의 제조과정
PL188054B1 (pl) Nowe Na-2-(4-nitrofenylosulfonylo) etoksykarbonyloaminokwasy i sposób wytwarzania nowych Nα-2-(4-nitrofenylosulfonylo)etoksykarbonyloaminokwasów
US20020151718A1 (en) Synthesis of pyrrole amides
ES2383861B1 (es) Procedimiento de síntesis de intermedios de crambescidinas, de cimipronidina y de sus derivados.
KR101492351B1 (ko) 함불소 카바메이트기를 가지는 아미노산 아미드 유도체의 제조방법, 그 제조 중간체, 및 에틸렌디아민 유도체의 제조방법
Schmél et al. N-(9-fluorenylmethoxycarbonyl)-L-serine amide
FR2589860A1 (fr) Nouveau procede de preparation des n-nitrosourees
JPS5838243A (ja) フエニルエステル類
EP1150956A1 (en) Non-nucleoside reverse transcriptase inhibitors
CZ287849B6 (cs) Steroidní deriváty užitečné jako skelety pro tvorbu nepeptidových knihoven, způsob jejich výroby a jejich použití

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E601 Decision to refuse application